Overview

Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine
Taxane